Quarterly report pursuant to Section 13 or 15(d)

NON CONTROLLING INTEREST (Tables)

NON CONTROLLING INTEREST (Tables)

6 Months Ended

Jun. 30, 2024

NON CONTROLLING INTEREST

Schedule of net loss attributable to non-controlling interest

		BioCorRx Pharmaceuticals, Inc.				Joseph DeSanto MD
Net loss		$	(67,251	)		$	(1,072	)
Average Non-controlling interest percentage of profit/losses			24.2	%			35.0	%
Net loss attributable to the non-controlling interest		$	(16,275	)		$	(375	)

		BioCorRx Pharmaceuticals, Inc.				Joseph DeSanto MD
Net loss		$	(1,849	)		$	(1,881	)
Average Non-controlling interest percentage of profit/losses			24.2	%			35.0	%
Net loss attributable to the non-controlling interest		$	(448	)		$	(658	)

		BioCorRx Pharmaceuticals, Inc.				Joseph DeSanto MD
Net loss		$	(68,800	)		$	(1,964	)
Average Non-controlling interest percentage of profit/losses			24.2	%			35.0	%
Net loss attributable to the non-controlling interest		$	(16,650	)		$	(687	)

		BioCorRx Pharmaceuticals, Inc.				Joseph DeSanto MD
Net loss		$	(3,296	)		$	(3,550	)
Average Non-controlling interest percentage of profit/losses			24.2	%			35.0	%
Net loss attributable to the non-controlling interest		$	(798	)		$	(1,242	)

Schedule of changes in non controlling interest

Balance, December 31, 2023		$	(128,834	)
Net loss attributable to the non-controlling interest			(17,337	)
Balance, June 30, 2024			(146,171	)

Balance, December 31, 2022		$	(125,257	)
Net loss attributable to the non-controlling interest			(2,040	)
Balance, June 30, 2023			(127,297	)